Medical groups question price of new hep C drug

March 11, 2014

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences.

A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" treatment when compared with older drugs for the blood borne virus. The vote was part of a broader review of new hepatitis C drugs by the California Technology Assessment Forum. The insurer-affiliated group assesses the and effectiveness of new medical treatments.

The group estimates that replacing currently used hepatitis C drugs with Gilead's Sovaldi would raise California drug costs between $18 billion and $29 billion per year. The drug costs $84,000 for one 12-week course of treatment.

Explore further: Gilead buys US pharma rival Pharmasset

Related Stories

Gilead buys US pharma rival Pharmasset

November 21, 2011

US biotech firm Gilead Sciences announced plans Monday to acquire rival Pharmasset, a group specializing in treatments for AIDS and hepatitis, for $11 billion.

FDA reviews two promising new drugs for hepatitis C

October 22, 2013

Doctors may soon have two new drug options to treat patients with hepatitis C, just as the liver-destroying virus becomes a major public health issue for millions of Americans reaching retirement age.

US panel backs Gilead Sciences' hepatitis C drug (Update)

October 23, 2013

U.S. Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions infected with the liver-destroying virus.

US group seeks to block Gilead drug patent in India

November 24, 2013

A US-based patient rights group said Saturday it has sought to block a bid by California-based Gilead Sciences to obtain an Indian patent for a potentially blockbuster drug to treat hepatitis C.

US approves breakthrough hepatitis C drug (Update)

December 6, 2013

U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.

Doctor details two new hepatitis C drugs

December 20, 2013

In the last three weeks, the Food and Drug Administration has approved two new drugs that are expected to dramatically improve treatment of chronic hepatitis C, a liver-damaging viral infection that afflicts more than 3.2 ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.